Previous 10 | Next 10 |
Nevro to Present at Wells Fargo Virtual Healthcare Conference Friday, September 10, 2021 at 8:00 am Eastern Time / 5:00 am Pacific Time PR Newswire REDWOOD CITY, Calif. , Aug. 23, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device com...
The shares of medical device makers have come under pressure in morning hours after Texas Governor Greg Abbott encouraged the hospitals to consider postponing certain elective medical procedures to make room for rising COVID-19 patients in the state. The seven-day average of COVID-19 hospital...
Specialty medical device maker Nevro (NYSE: NVRO) had an awful Thursday, with its shares collapsing by over 24% in late afternoon trading. Investors were punishing the company for a worse-than-expected second-quarter earnings report. In terms of headline numbers, Nevro's perform...
Gainers: Profound Medical (NASDAQ:PROF) +28%, STAAR Surgical (NASDAQ:STAA) +19%, AdaptHealth (NASDAQ:AHCO) +17%, Flora Growth (NASDAQ:FLGC) +16%, Invacare (NYSE:IVC) +15%. Losers: Inogen (NASDAQ:INGN) -32%, Karyopharm Therapeutics (NASDAQ:KPTI) ...
The following slide deck was published by Nevro Corp. in conjunction with their 2021 Q2 earnings call. For further details see: Nevro Corp. 2021 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. Nevro Corp (NYSE: NVRO) Q2 2021 Earnings Call Aug 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Nevro Corp (NVRO) Q2 2021 Earnings Call Transcript
Nevro Corp. (NVRO) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Julie Dewey – Vice President-Investor Relations and Corporate Communications Keith Grossman – Chairman, Chief Executive Officer and President Rod MacLeod – Chief Financial O...
Nevro (NYSE:NVRO): Q2 GAAP EPS of -$0.62 beats by $0.11. Revenue of $102.33M (+81.5% Y/Y) misses by $0.5M. Non-GAAP Adjusted EBITDA of $3.0 Million The company provides Q3 2021 Revenue guidance of $90 Million to $93 Million (consensus $102.83M) Q3 Non-GAAP Adjusted EBITDA guidance of negative...
Nevro Reports Second Quarter 2021 Financial Results and Provides Third Quarter of 2021 Guidance PR Newswire REDWOOD CITY, Calif. , Aug. 4, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evide...
peterschreiber.media/iStock via Getty Images Nevro Corp. ([[NVRO]] +5.4%) continues to trade higher after the company announced the FDA approval of its Senza Spinal Cord Stimulation ((SCS)) system as a treatment of chronic pain linked to Painful Diabetic Neuropathy ((PDN)). Commenting on...
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...